January 20, 2022

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

TOKYO, Jan 20, 2022 – (JCN Newswire via SEAPRWire.com) – Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United…

Read More

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications

TOKYO, May 7, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd.and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the…

Read More

December 17, 2020

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Demonstrated Statistically Significant Improvement in OS, PFS and ORR

TOKYO, Dec 17, 2020 – (JCN Newswire) – Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United…

Read More